ESR1 and breast cancer: ESR1 mutations in advanced BC patients have already been described in 2013 [274,279,280,281,282] with most mutations occurring in the ligand-binding domain, resulting in a ligand-independent and constitutively activated receptor associated with aggressive disease biology [278].